June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
The Deranged Vitreous Biochemistry in Diabetic Retinopathy: Prabable Diagnostic, Prognostic and Therapeutic Targets.
Author Affiliations & Notes
  • Nikhil Shri Sahajpal
    PHARMACEUTICAL SCIENCES, GURU NANAK DEV UNIVERSITY, Amritsar, Punjab, India
    Dr Sohan Singh Eye Hospital, Amritsar, Punjab, India
  • Vipan Vig
    Dr Sohan Singh Eye Hospital, Amritsar, Punjab, India
  • Preetam Singh
    Dr Sohan Singh Eye Hospital, Amritsar, Punjab, India
  • Rajbir Singh
    Dr Sohan Singh Eye Hospital, Amritsar, Punjab, India
  • Subheet Jain
    PHARMACEUTICAL SCIENCES, GURU NANAK DEV UNIVERSITY, Amritsar, Punjab, India
  • Footnotes
    Commercial Relationships   Nikhil Sahajpal, None; Vipan Vig, None; Preetam Singh, None; Rajbir Singh, None; Subheet Jain, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 5211. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Nikhil Shri Sahajpal, Vipan Vig, Preetam Singh, Rajbir Singh, Subheet Jain; The Deranged Vitreous Biochemistry in Diabetic Retinopathy: Prabable Diagnostic, Prognostic and Therapeutic Targets.. Invest. Ophthalmol. Vis. Sci. 2017;58(8):5211.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The etiology and progression of diabetic retinopathy (DR) remains a complex enigma. In DR patients, the vitreous clinical biochemistry has not yet been reported. The biochemical changes occurring at the site of DR are paramount in understanding the pathophysiology of DR. We hypothesize a derangement in the vitreous biochemistry (metabolites, antioxidants & proliferative markers) in DR patients, which would enhance the understanding of the progression of DR.

Methods : A prospective, cross sectional study of vitreous and plasma samples from DR patients (n=29) and controls (C) (n=27) undergoing vitrectomy. Each sample was analyzed for biochemical markers (glucose, cholesterol, triglycerides, total protein (TP), urea, creatinine, albumin, aspartate transaminase, alanine transaminase, micro protein urea, uric acid, γ glutamyl transferase, phosphate, calcium, creatine kinase (CK) and lactate dehydrogenase-LDH) using the Clinical chemistry analyzer (Benespera, USA), zeaxanthin (ZEA-most abundant antioxidant in the macula of eye) using HPLC (Agilent Technologies, USA) and proliferative markers [vascular endothelial growth factor (VEGF) and VEGF receptor 1 (VEGFR1)] using ELISA (Ray Biotech, USA). Two tailed Student’s t-test was used for statistical analysis.

Results : Glucose (DR:49.27±27.78mg/dl, C:20.81±14.38mg/dl; P<0.001), cholesterol (DR:1.24±1.72 mg/dl, C:0.29±0.95 mg/dl; P<0.05), TP (DR 0.25±0.24 g/dl, C:0.1±0.11 g/dl; P<0.01), CK (DR:5.2±7.38 U/L, C:0.15±0.52 U/L; P<0.05) and LDH (DR:175.8±125.70 U/L, C:40.42±33.55 U/L; P< 0.01) were significantly increased in vitreous of DR vs. C. Creatinine was significantly (P<0.01) increased in plasma of DR vs. C. ZEA was significantly (P< 0.01) reduced in vitreous of DR (0.28±0.04 µg/ml) vs. C (0.36±0.09 µg/ml). ZEA was significantly (P<0.01) reduced in plasma of DR (0.32±0.04 µg/ml) vs. C (0.38±0.05 µg/ml). ZEA was significantly (P<0.05) reduced in DR vitreous vs. DR plasma. Further, trends reported in literature were observed for VEGF and VEGFR1 markers with no significant differences.

Conclusions : DR is a morbid disorder with evident deranged vitreous biochemistry typical of a metabolic disorder. Glucose, Cholesterol, TP, CK and LDH may be novel diagnostic/therapeutic targets in DR. ZEA, is a novel antioxidant and might be a critical diagnostic marker of therapeutic value in DR.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×